Everest Medicines Sets Up ESG Committee, Names Four Directors Including Chairman Yifang Wu

Bulletin Express09-28 22:43

Everest Medicines announced the formation of an Environmental, Social and Governance (ESG) Committee, effective 28 September 2026.

The new board‐level body will comprise at least three members and initially includes Chairman and Executive Director Yifang Wu, Executive Director Yongqing Luo, Non-executive Director Yue Wang and Independent Non-executive Director Yifan Li. Yifang Wu will serve as committee chair.

According to the filing, the ESG Committee’s terms of reference will be published on both the Hong Kong Stock Exchange and company websites.

As of the announcement date, the board consists of nine directors: three executive directors (Yifang Wu, Yongqing Luo, Ian Ying Woo), three non-executive directors (Wei Fu, Xin Sun, Yue Wang) and three independent non-executive directors (Hoi Yam Chui, Yifan Li, Shidong Jiang).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment